TICKERNOMICS Sign up
Last Update: 2024-12-27 15:28:11
Aadi Bioscience Inc. ( AADI ) https://aadibio.com
3.10USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
AADI
47.62%
SPY
32.66%
-87.13%
AADI
SPY
108.59%
-64.37%
AADI
SPY
302.52%
AADI
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
83.83
22.16
0.29
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.36
3.34
1.22
-127.09
0.00
-0.36
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-185.98
100.00
-237.82
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.5584
-131.05
-45.63
0.88
Other Earnings and Cash Flow Stats:
Aadi Bioscience Inc. ( AADI ) Net Income TTM ($MM) is -61.69
Aadi Bioscience Inc. ( AADI ) Operating Income TTM ($MM) is -66.22
Aadi Bioscience Inc. ( AADI ) Owners' Earnings Annual ($MM) is -63.30
Aadi Bioscience Inc. ( AADI ) Current Price to Owners' Earnings ratio is -0.89
Aadi Bioscience Inc. ( AADI ) EBITDA TTM ($MM) is -66.03
Aadi Bioscience Inc. ( AADI ) EBITDA Margin is -237.82%
Capital Allocation:
Aadi Bioscience Inc. ( AADI ) has paid 0.00 dividends per share and bought back -0.094643999999999 million shares in the past 12 months
Aadi Bioscience Inc. ( AADI ) has reduced its debt by 0.423 million USD in the last 12 months
Capital Structure:
Aadi Bioscience Inc. ( AADI ) Interest-bearing Debt ($MM) as of last quarter is 0
Aadi Bioscience Inc. ( AADI ) Annual Working Capital Investments ($MM) are 6
Aadi Bioscience Inc. ( AADI ) Book Value ($MM) as of last quarter is 68
Aadi Bioscience Inc. ( AADI ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
Aadi Bioscience Inc. ( AADI ) has 30 million in cash on hand as of last quarter
Aadi Bioscience Inc. ( AADI ) has 15 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Aadi Bioscience Inc. ( AADI ) has 27 common shares outstanding as of last quarter
Aadi Bioscience Inc. ( AADI ) has 0 million USD of preferred stock value
Academic Scores:
Aadi Bioscience Inc. ( AADI ) Altman Z-Score is -3.37 as of last quarter
Aadi Bioscience Inc. ( AADI ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Aadi Bioscience Inc. ( AADI ) largest shareholder is State Street Corporation owning 296369 shares at 0.92 ($MM) value
Lennon David James(an insider) Sold 9689 shares of Aadi Bioscience Inc. ( AADI ) for the amount of $18796.66 on 2024-10-03
9.97% of Aadi Bioscience Inc. ( AADI ) is held by insiders, and 62.65% is held by institutions
Aadi Bioscience Inc. ( AADI ) went public on 2017-08-08
Other Aadi Bioscience Inc. ( AADI ) financial metrics:
FCF:-65.57
Unlevered Free Cash Flow:-69.27
EPS:-1.86
Operating Margin:-185.98
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-72.87
Beta:0.88
Buffet's Owners Earnings:-63.30
Price to Owner's Earnings:-0.89
About Aadi Bioscience Inc. ( AADI ) :
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.